ARUP Licenses Ipsogen Leukemia MDx IP | GenomeWeb

NEW YORK (GenomeWeb News) – French molecular diagnostics company Ipsogen has licensed rights to use gene variants for diagnosing leukemia to ARUP Laboratories, a reference lab that is part of the University' of Utah's Department of Pathology.

Under the agreement, ARUP licensed non-exclusive rights to use the group of JAK2 gene variations to screen for myeloproliferative neoplasms (MPN), a group of leukemias, in the US, Ipsogen said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.